CollPlant Biotechnologies
CLGN
16 hedge funds and large institutions have $51.9M invested in CollPlant Biotechnologies in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.
113% more capital invested
Capital invested by funds: $24.4M → $51.9M (+$27.5M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
7% more funds holding
Funds holding: 15 → 16 (+1)
0.56% more ownership
Funds ownership: 1.83% → 2.39% (+0.56%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.82M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$208K |
| 4 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$79.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$734K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$265K |
| 3 |
FA
Friess Associates
Greenville,
Delaware
|
-$240K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$229K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$134K |
CLGN Hedge Fund Activity: Q2 2021 in Review
16 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q2 2021, worth a combined $51.9M — up 113% from $24.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CLGN positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Roumell Asset Management, opening a new position worth an estimated $9M. The largest seller was Brown Advisory, exiting entirely with an estimated $734K sold.
- 16 institutional investors held CollPlant Biotechnologies (CLGN) as of Q2 2021, up from 15 in Q1 2021.
- Funds reported $51.9M of CollPlant Biotechnologies stock for Q2 2021, up 113% quarter-over-quarter.
- 6 funds opened new CollPlant Biotechnologies positions in Q2 2021 and 5 closed out, a net change of +1 holder.
- The largest CollPlant Biotechnologies buyer in Q2 2021 was Roumell Asset Management, an estimated $9M added.
- The largest CollPlant Biotechnologies seller in Q2 2021 was Brown Advisory, an estimated $734K sold.
Based on aggregated 13F filings for Q2 2021.